Oragenics Inc 8-K, filed Apr 16, 2024
Oragenics Inc (OGEN)
About this 8-K
Oragenics Inc filed this 8-K on April 16, 2024, reporting on events of April 15, 2024.
Items reported
- Item 5.08: Shareholder director nominations
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date
of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.08 Shareholder Director Nominations
The Board of Directors of the Company has established July 15, 2024 as the date of the Company’s 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”). Because the date of the 2023 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s 2022 Annual Meeting of Shareholders (the “2022 Annual Meeting”), in accordance with Rule 14a−5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing shareholders of such change. The record date, time and location of the 2023 Annual Meeting will be as set forth in the Company’s proxy statement for the 2023 Annual Meeting.
Because the date of the 2023 Annual Meeting has been changed by more than 30 days from the anniversary of the 2022 Annual Meeting of Shareholders, a new deadline has been set for submission of proposals by Shareholders intended to be included in the Company’s 2023 proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the 2023 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act, must be received by the Company on or before May 20,2024 which the Company believes is a reasonable time before it expects to begin to print and send its proxy materials. Shareholders must deliver the proposals or nominations to the Company’s principal executive offices at the following address: Oragenics, Inc., Attn: Corporate Secretary, 1990 Main Street, Suite 750, Sarasota, Florida 34236.
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15th day of April, 2024.
| ORAGENICS, INC. | ||
(Registrant)
| ||
| BY: | /s/ Janet Huffman | |
| Janet Huffman | ||
| Chief Financial Officer | ||